Portal de Periódicos da CAPES

Evaluating the response to glatiramer acetate in relapsing–remitting multiple sclerosis (RRMS) patients

2014; SAGE Publishing; Volume: 20; Issue: 12 Linguagem: Inglês

10.1177/1352458514527863

1477-0970

Jordi Río, Àlex Rovira, Mar Tintoré, Jaume Sastre‐Garriga, Joaquín Castilló, Cristina Auger, Carlos Nos, Manuel Comabella, Carmen Tur, Ángela Vidal‐Jordana, Xavier Montalbán,

Systemic Lupus Erythematosus Research

Background: In patients with relapsing–remitting multiple sclerosis (RRMS), a scoring system based on new magnetic resonance imaging (MRI) active lesions, relapses and sustained disability progression after a 1-year treatment with IFNβ predicted patient disability progression over time; however, this score had not been tested in patients receiving glatiramer acetate (GA). Objective: The objective of this study was to evaluate whether this previous scoring system can also be applied to patients treated with GA. Methods: This was a prospective, longitudinal study of 151 RRMS patients treated with GA. Their scores were constructed, based on the clinical and MRI activity after 1 year of therapy. Regression analysis was performed, in order to identify the response variables. Results: The total possible score range was 0–3. Patients with a score of ≥ 2 and those with clinical activity (with or without MRI activity) during their first year of treatment were at increased risk of continuing with relapses and/or sustained disability in the next 2 years (odds ratio (OR): 38.8; p < 0.0001 and OR: 7.8; p < 0.009, respectively). Conclusions: In RRMS patients treated with GA, a combination of clinical activity measures may have prognostic value for identifying patients with disease activity in the next 2 years of therapy.